The platform for GPCR pharmacology built on the data the field has been missing — and designed to turn its most consequential unknowns into decisions.
Affinity tells you a molecule binds.
It doesn't tell you whether binding does anything.
The Problem
The industry's primary filter is affinity — a measure of how tightly a drug candidate binds to its target protein. It drives medicinal chemistry, computational design, and AI optimization alike.
A molecule can bind tightly and produce no biological effect. It can bind weakly and transform a patient's life. Affinity predicts neither.
The conformational engagement of a drug at its target — whether binding actually moves the receptor, and how — is the measurement that determines whether a candidate works. It is possible to measure. It has simply never been done systematically, at scale, and with the data infrastructure to make the results actionable.
The data doesn't exist. Kinovi exists to capture it — and make it decisive.
Spent by the top 20 pharmaceutical companies on clinical programs terminated in 2024 alone.
Deloitte, 2024
Of all clinical trial failures are efficacy failures — the drug didn't work as the binding data suggested it would.
Until now.
Built to be used. Built to compound. Built to last.
Scientific Foundation
The science is peer-reviewed.
Selected from 50+ peer-reviewed publications.
Combinatorial Pattern Response of Bioelectronic Nose for the Detection of Real Nerve Agents
Joseph began his career at Pfizer Neuroscience, working in medicinal chemistry on Alzheimer's and schizophrenia programs — synthesizing candidates, watching programs advance and fail, and developing a first-hand understanding of what the field measures and what it consistently misses. The question that stayed with him: what was never measured?
He went on to earn his PhD at MIT in the Swager lab, where he developed a deep specialization in nanomaterial sensors and field-effect transistors — and more specifically, in how to conceive of novel sensing systems from first principles. That methodology drove the design of Confidynt™: starting from what the sensor needed to do, and working backward to the technology stack capable of doing it.
Prior to Kinovi, Joseph founded Numo Health, where he advanced a novel approach to early disease detection through primary translational research conducted at MGH Cancer Center.
Joseph holds 14 issued patents and 10 pending across US and international jurisdictions. Beyond Kinovi, he works with founders and organizations pursuing consequential problems at the edges of what medicine currently addresses.
We're building something consequential. If you are too, let's talk.